. Cas9 and sgRNA expression cassette sequences used in this study. (pGF-IVL1220) were transformed into yeast. Cultures were pre-induced overnight in raffinose/sucrose lacking uracil and leucine, back-diluted to medium containing galactose and lacking uracil and leucine, and were grown for 4.5 hr at 30°C. Cells were harvested, washed with water, and imaged by fluorescence microscopy. Representative images are shown. Scale bar, 3 μm. Table S1 . Yeast strains used in this study. or the same construct with AcrIIA4 (pGF-IVL1411) were generated [4] , PCR amplified in overlapping fragments, DpnI treated, integrated into GFY-2383, and colonies were selected for survival on SD-HIS medium and sensitivity to G418. 384 bp of the MET25 promoter were used. Second, the HIS5 marker was replaced with the Kan R MX-based cassette using an amplified fragment containing CDC10(t)::prMX::Kan R ::MX(t) (from pGF-IVL1412). There is a (u1) site downstream of the MX(t) sequence rather than a (u2) site. d Construction of GFY-3104 and GFY-3268 included use of enzymatically dead Cas9 (D10A H840A). A modified site directed mutagenesis protocol [5] was used in introduce substitutions to the ORF in a pUC57 vector prior to in vivo plasmid assembly. The LactC2 [6, 7] domain was amplified from pGF-IVL687. The constructs were integrated into the yeast genome as previously described. Table S2 . Plasmids used in this study.
S. pyogenes

Strain Genotype Reference
BY4741
Plasmid
Description Reference pRS425 2, LEU2 [8] pRS316 CEN URA3 [9] pGF-V809 ). Second, substitutions were introduced using PCR. Third, the entire construct was sub-cloned to the pRS316 vector using the flanking NotI/SpeI sites.
f The sgRNA(u1) includes the crRNA: 5' CGGTGGACTTCGGCTACGTA 3'. g The sgRNA(mCherry) includes the crRNA: 5' CAAGGAGTTCATGCGCTTCA 3'. h For constructs containing an N-terminal or C-terminal deletion, residues were removed during in vivo plasmid assembly. D14A, no effect on inhibition;
D14A/Y15A f , strong decrease in inhibition; E40A, no effect The in vivo assay used in this study (Fig. 5) to provide a quantification of AcrIIA4 inhibitory function S. pyogenes Cas9 is by halting an active gene drive in diploid yeast after 5 hrs of nuclease induction. c This study [12] used a GST pull-down assay to determine preloaded sgRNA-bound Cas9/AcrIIA4 binding (AcrIIA4 was fused to GST). Our interpretation of the amount of bound AcrIIA4 is from Extended Data Figure 3 , part B, by comparing to control lanes. d This study [12] utilized an in vitro DNA cleavage assay to illustrate the inhibitory effect of AcrIIA4 on Cas9. Our interpretation of the level of (remaining) inhibition of Cas9 nuclease activity is based Extended Data Figure 3 , part C, by comparing to control lanes. e ND, not determined. f For several double mutant combinations, we tested the sgRNA loaded dCas9/AcrIIA4 association by an in vivo fluorescence localization assay (Fig. 6 ). All three mutants displayed a total loss of Cas9 association as determined by a lack of PM-localization. g This study [13] performed an in vitro MBP-binding assay to Cas9 (AcrIIA4 fused to MBP). Our interpretation of the amount of bound AcrIIA4 is from Figures 3G and S3E by comparing to control lanes. h This study [13] utilized an in vitro DNA cleavage assay using sgRNA-bound Cas9 and AcrIIA4. Our interpretation of the amount of AcrIIA4 inhibitory activity is from Figures 3H and S3F , by comparing to control lanes.
